MedTrace Logo

Analysis of Lipid Biomarkers of Exposure and Host Response

NCT00493831 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-09-07

Study results available
· View outcomes & findings →

Summary

The purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (EBC) biomarkers for use in studies designed to evaluate harm reduction strategies of smoking. This will be accomplished by measuring selected markers in EBC believed related to the pathogenesis of lung disease before and after a smoking cessation intervention.

Conditions

  • Cigarette Smoking

Interventions

DRUG

nicotine polacrilex, transdermal system or inhaler

on label use of Nicotine replacement therapy (NRT)

Sponsors & Collaborators

  • Lorillard Tobacco Company

    collaborator INDUSTRY

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Stephen I Rennard, MD · University of Nebraska

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-23
Primary Completion
2007-09-09
Completion
2007-09-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493831 on ClinicalTrials.gov